A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Description

This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metastatic castrate resistant prostate cancer (mCRPC) with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes.

Conditions

Advanced Solid Tumor

Talk to us

Study Overview

On this page

Study Details

Study overview

This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metastatic castrate resistant prostate cancer (mCRPC) with deleterious/suspected deleterious mutations of select homologous recombination repair (HRR) genes.

A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Condition
Advanced Solid Tumor
Intervention / Treatment

-

Contacts and Locations

Irvine

University California Irvine, Irvine, California, United States, 92868

San Francisco

University of California San Francisco (UCSF), San Francisco, California, United States, 94158

Denver

Sarah Cannon Research Institute Health One, Denver, Colorado, United States, 80218

New Haven

Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut, United States, 06511

Celebration

Advent Health Research Institute, Celebration, Florida, United States, 34747

Detroit

Karmanos Cancer Institute, Detroit, Michigan, United States, 48201

Saint Louis

Washington University - Siteman Cancer Center, Saint Louis, Missouri, United States, 63110

Ithaca

Cayuga Medical Center, Ithaca, New York, United States, 14850

Charleston

Medical University of South Carolina (MUSC) - Hollings CC, Charleston, South Carolina, United States, 29425

Nashville

Sarah Cannon Research Institue Oncology, Nashville, Tennessee, United States, 37203

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Any investigational or approved anti-cancer therapies administered within 28 days/ before the first dose of IMP1734
  • * Have received prior PARP1 selective inhibitors
  • * Mean resting QTcF \> 470 ms or QTcF \< 340 ms
  • * Active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • * Infections
  • * Any known predisposition to bleeding
  • * Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability

Ages Eligible for Study

18 Years to 89 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Eikon Therapeutics,

Viola Chen, MD, STUDY_DIRECTOR, Eikon Therapeutics

Study Record Dates

2026-12-01